Sweden-based women’s health company Gedea Biotech has completed a clinical trial, the NEFERTITI-2 study, for the treatment of ...

ViiV Healthcare has announced promising results from two Phase IIa studies of investigational antiretroviral therapies, VH184 ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% ...

California commercial-stage biopharma firm Geron Corporation (Nasdaq: GERN) has announced that Dr John “Chip” Scarlett, ...

UK-based Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today ...

Independent French drugmaker Pierre Fabre Laboratories and Switzerland-based RedRidge Bio have announced an exclusive R&D ...

Italian biomedical charity Fondazione Telethon, which is focused on rare genetic diseases, revealed it has submitted a ...

Rajeev Juneja, vice chairman and managing director of Mumbai, Indian-based drugmaker Mankind Pharma (NSE: MANKIND), today ...

Alliance Pharma has accepted a final increased cash offer from investment firm DBAY Advisors, valuing the UK-based ...

Harbour BioMed (HKEX: 02142) has appointed Michael Patten as chief strategy officer, responsible for overseeing global ...

Shares of Danish biotech Zealand Pharma (Nasdaq: ZEAL) were up 30% at 635.50 kroner by early afternoon, on news of a potentially lucrative licensing deal with Swiss pharm giant Roche (ROG: SIX). Under ...